Tetraphase Pharmaceuticals, Inc. (TTPH) Price Target Raised to $24.00 at BMO Capital Markets
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) had its price objective hoisted by BMO Capital Markets from $13.00 to $24.00 in a report issued on Wednesday. They currently have an outperform rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also commented on TTPH. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, July 6th. HC Wainwright assumed coverage on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They issued a buy rating and a $15.00 target price for the company. Stifel Nicolaus raised shares of Tetraphase Pharmaceuticals from a hold rating to a buy rating and raised their target price for the company from $8.00 to $15.00 in a research report on Wednesday, July 26th. Needham & Company LLC reaffirmed a hold rating on shares of Tetraphase Pharmaceuticals in a research report on Thursday, July 27th. Finally, BidaskClub downgraded shares of Tetraphase Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. Tetraphase Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $12.96.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded up 0.65% during trading on Wednesday, hitting $7.80. 1,041,301 shares of the stock traded hands. The company’s market capitalization is $398.21 million. Tetraphase Pharmaceuticals has a one year low of $3.11 and a one year high of $9.93. The company’s 50 day moving average is $6.68 and its 200 day moving average is $7.29.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The company had revenue of $1.59 million for the quarter, compared to analyst estimates of $1.54 million. During the same quarter in the previous year, the business earned ($0.47) earnings per share. The company’s revenue was up 28.2% on a year-over-year basis. On average, equities analysts forecast that Tetraphase Pharmaceuticals will post ($2.61) EPS for the current fiscal year.
In related news, insider Jacques Dumas sold 17,500 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total value of $105,000.00. Following the completion of the transaction, the insider now owns 17,500 shares of the company’s stock, valued at $105,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 5.50% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in TTPH. Tekla Capital Management LLC grew its position in shares of Tetraphase Pharmaceuticals by 422.2% in the 1st quarter. Tekla Capital Management LLC now owns 1,004,322 shares of the biopharmaceutical company’s stock valued at $9,230,000 after acquiring an additional 812,000 shares during the period. Numeric Investors LLC grew its position in shares of Tetraphase Pharmaceuticals by 1,363.3% in the 2nd quarter. Numeric Investors LLC now owns 754,364 shares of the biopharmaceutical company’s stock valued at $5,379,000 after acquiring an additional 702,812 shares during the period. EcoR1 Capital LLC bought a new position in shares of Tetraphase Pharmaceuticals in the 2nd quarter valued at about $4,516,000. Dimensional Fund Advisors LP grew its position in shares of Tetraphase Pharmaceuticals by 73.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,101,255 shares of the biopharmaceutical company’s stock valued at $7,853,000 after acquiring an additional 466,955 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Tetraphase Pharmaceuticals by 16.4% in the 1st quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock valued at $15,061,000 after acquiring an additional 230,420 shares during the period. 41.73% of the stock is owned by institutional investors.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.